8-K filed July 25, 2023, 7:59 PM ET CIK 0001113148

other material confidence high sentiment negative materiality 0.95

INFINITY PHARMACEUTICALS, INC.: restructuring charge — Infinity Pharma cuts 78% of workforce, three directors resign, seeks strategic alternative for eganelisib

INFINITY PHARMACEUTICALS, INC.

Headcount reduced by 21 positions (78% of workforce); expects $3.4M severance charge in Q3 2023.
Three board members (Agresta, Kango, Schwartz) resign; remaining five directors serve without compensation.
Company hires SSG Capital Advisors to lead strategic process to maximize value of eganelisib.
Company evaluating withdrawal of Nasdaq delisting appeal; withdrawal likely leads to stock delisting.
Merger agreement with MEI Pharma terminated; seeking alternative strategic transaction for eganelisib.

item 2.05 item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Sujay R. Kango

Director

INFINITY PHARMACEUTICALS, INC.

Effective: 2023-07-24
Filed: July 25, 2023, 7:59 PM ET

On July 24, 2023, each of Samuel Agresta, Sujay R. Kango and Brian Schwartz resigned from the Board, effective immediately.

Departed

Samuel Agresta

Director

INFINITY PHARMACEUTICALS, INC.

Effective: 2023-07-24
Filed: July 25, 2023, 7:59 PM ET

On July 24, 2023, each of Samuel Agresta, Sujay R. Kango and Brian Schwartz resigned from the Board, effective immediately.

Departed

Brian Schwartz

Director

INFINITY PHARMACEUTICALS, INC.

Effective: 2023-07-24
Filed: July 25, 2023, 7:59 PM ET

On July 24, 2023, each of Samuel Agresta, Sujay R. Kango and Brian Schwartz resigned from the Board, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Sujay R. Kango resigned as Director at INFINITY PHARMACEUTICALS, INC..

Action: resigned
Role: Director

Exact text from the filing

On July 24, 2023, each of Samuel Agresta, Sujay R. Kango and Brian Schwartz resigned from the Board, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Samuel Agresta resigned as Director at INFINITY PHARMACEUTICALS, INC..

Action: resigned
Role: Director

Exact text from the filing

On July 24, 2023, each of Samuel Agresta, Sujay R. Kango and Brian Schwartz resigned from the Board, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Brian Schwartz resigned as Director at INFINITY PHARMACEUTICALS, INC..

Action: resigned
Role: Director

Exact text from the filing

On July 24, 2023, each of Samuel Agresta, Sujay R. Kango and Brian Schwartz resigned from the Board, effective immediately.

View on SEC.gov

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

INFINITY PHARMACEUTICALS, INC. announced a restructuring with charges of approximately $3.4 million (21 positions, representing approximately 78% of the Company’s workforce).

Type: restructuring
Charge: approximately $3.4 million
Headcount: 21 positions, representing approximately 78% of the Company’s workforce

Exact text from the filing

reduction is expected to be completed by the end of the third quarter of 2023. The Company expects to incur a one-time charge in the third quarter of 2023 of approximately $3.4 million in severance and restructuring costs in connection with the workforce reduction. This charge primarily relates to severance payments and employee benefits. The estimates of

View on SEC.gov

Browse all restructurings & charges →

Source: SEC EDGAR

accession 0001140361-23-036062

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.